Pelareorep Shows Dual HPV and T-Cell Immune Responses in Anal Cancer
Oncolytics Biotech announced positive translational data from SITC 2026 showing that its oncolytic virus pelareorep, combined with a checkpoint inhibitor, increases HPV-16-specific T cells and tumor-infiltrating lymphocytes in anal cancer patients, potentially broadening its efficacy across HPV-driven malignancies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed